<p>隨着美國市場在科技股承壓和主要指數從歷史高點回落的情況下出現波動，投資者在對人工智能泡沫的擔憂中密切關注機會。在如此動盪的環境中，識別潛在的被低估股票對於那些尋求利用市場低效和價格差異的投資者來説變得至關重要。</p>
<h3>基於現金流的美國十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>Webull (BULL)</td>
<td>$9.16</td>
<td>$17.89</td>
<td>48.8%</td>
</tr>
<tr>
<td>UMB Financial (UMBF)</td>
<td>$118.17</td>
<td>$232.81</td>
<td>49.2%</td>
</tr>
<tr>
<td>Sportradar Group (SRAD)</td>
<td>$23.11</td>
<td>$45.87</td>
<td>49.6%</td>
</tr>
<tr>
<td>Schrödinger (SDGR)</td>
<td>$18.05</td>
<td>$35.42</td>
<td>49%</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.75</td>
<td>$3.43</td>
<td>49%</td>
</tr>
<tr>
<td>Motorcar Parts of America (MPAA)</td>
<td>$13.77</td>
<td>$26.53</td>
<td>48.1%</td>
</tr>
<tr>
<td>Mobileye Global (MBLY)</td>
<td>$11.07</td>
<td>$21.30</td>
<td>48%</td>
</tr>
<tr>
<td>Krystal Biotech (KRYS)</td>
<td>$244.65</td>
<td>$469.32</td>
<td>47.9%</td>
</tr>
<tr>
<td>FirstSun Capital Bancorp (FSUN)</td>
<td>$37.79</td>
<td>$73.32</td>
<td>48.5%</td>
</tr>
<tr>
<td>Columbia Banking System (COLB)</td>
<td>$29.24</td>
<td>$57.69</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 211 只被低估美國股票的完整列表。</p>
<p>在這裏，我們突出了一些我們偏好的股票。</p>
<h2>Protagonist Therapeutics (PTGX)</h2>
<p><strong>概述：</strong> Protagonist Therapeutics, Inc.是一家生物製藥公司，專注於開發用於血液學和血液疾病以及炎症和免疫調節疾病的肽類治療藥物，市值為 59.6 億美元。</p>
<p><strong>運營：</strong> 該公司通過其生物技術部門產生收入，特別專注於初創企業，收入達到 2.0922 億美元。</p>
<p><strong>公允價值折扣估算：</strong> 18.3%</p>
<p>Protagonist Therapeutics 的交易價格為 95.35 美元，低於其 116.77 美元的估算公允價值，表明基於現金流的潛在低估。該公司預計未來三年年收益增長將達到 44%，超過更廣泛市場的增長預期。儘管最近出現淨虧損和利潤率下降，Protagonist 的有前景的產品管線包括用於真性紅細胞增多症的 rusfertide，該藥物已獲得多個 FDA 認證並顯示出積極的三期結果。</p>
<ul>
<li>我們最近的增長報告提供了 Protagonist Therapeutics 商業前景的良好預測。</li>
<li>點擊這裏瞭解 Protagonist Therapeutics 的詳細財務健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>PTGX 截至 2025 年 12 月的折現現金流</p>
<h2>Atlantic Union Bankshares (AUB)</h2>
<p><strong>概述：</strong> Atlantic Union Bankshares Corporation 是一家銀行控股公司，旗下擁有 Atlantic Union Bank，為美國消費者和企業提供一系列銀行和金融服務，市值約為 52.2 億美元。</p>
<p><strong>運營：</strong> Atlantic Union Bankshares 通過其消費者銀行業務產生收入，收入為 4.1666 億美元，以及其批發銀行業務，貢獻 4.7499 億美元。</p>
<p><strong>公允價值折扣估算：</strong> 19.2%</p>
<p>Atlantic Union Bankshares 的交易價格為 36.65 美元，相較於其基於折現現金流分析的公允價值估算 45.36 美元被低估。該公司預計未來三年年收益增長將達到 41.5%，超過市場預期。然而，最近的股東稀釋和低預期的股本回報率帶來了挑戰。儘管存在這些問題，Atlantic Union 的股息收益率在最近提高至 4.5% 後仍然具有吸引力，得益於最近幾個季度強勁的淨利息收入增長。</p>
<ul>
<li>我們精心準備的 Atlantic Union Bankshares 增長報告暗示其未來財務前景可能比最近的結果更強勁。</li>
<li>點擊這裏深入瞭解 Atlantic Union Bankshares 的完整分析健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39dc53db-0edc-4efe-9bce-4b97187c1c94/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39dc53db-0edc-4efe-9bce-4b97187c1c94/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>AUB 截至 2025 年 12 月的折現現金流</p>
<h2>Tapestry (TPR)</h2>
<p><strong>概述：</strong> Tapestry, Inc.是一家在北美、大中華區、其他亞洲地區及國際市場提供配飾和生活方式品牌產品的公司，市值約為 252.1 億美元。</p>
<p><strong>運營：</strong> 該公司的收入來自其各個業務部門：Coach 為 58.6 億美元，Kate Spade 為 11.7 億美元，Stuart Weitzman 為 1.76 億美元。</p>
<p><strong>公允價值折扣估算：</strong> 10.5%</p>
<p>Tapestry 最近的財務表現突顯了其作為基於現金流的被低估股票的潛力。該公司報告第一季度淨收入大幅增加至 2.748 億美元，且每股收益顯著高於去年。儘管債務水平較高和內部人士拋售，Tapestry 的股票交易價格為 123.21 美元，低於估算的公允價值 137.73 美元，得益於未來三年年利潤增長預測為 24.6% 和自 2024 年 11 月以來總計 20 億美元的持續股票回購。</p>
<ul>
<li>我們編制的增長報告表明 Tapestry 的未來前景可能向好。</li>
<li>點擊探索我們在 Tapestry 資產負債表健康報告中的詳細發現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4cf6cfa0-4c9d-498d-a423-dd756aaefde7/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4cf6cfa0-4c9d-498d-a423-dd756aaefde7/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>TPR 截至 2025 年 12 月的折現現金流</p>
<h2>總結</h2>
<ul>
<li>點擊這裏解鎖我們基於現金流的 211 只被低估美國股票的全面列表。</li>
<li>擁有這些企業的股份？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受跨越每個大洲的市場情報免費訪問。</li>
</ul>
<h2>想探索一些替代方案嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以應對潛在的市場波動。</li>
<li>通過顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>國防與災難的移動基礎設施</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，覆蓋任何地方。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

AUB.PRA

<p>這篇文章討論了 2025 年 12 月三隻可能被低估的股票：Protagonist Therapeutics、Atlantic Union Bankshares 和 Tapestry。Protagonist Therapeutics 的交易價格低於其公允價值，且增長預測樂觀。Atlantic Union Bankshares 同樣被低估，預計將實現顯著的盈利增長。儘管債務水平較高，Tapestry 仍顯示出強勁的利潤增長。文章強調了在市場波動中識別被低估股票的重要性，並提供了一份基於現金流的 211 只被低估的美國股票的綜合名單</p>

<p>As the United States market experiences fluctuations with tech shares under pressure and major indices retreating from record highs, investors are keenly observing opportunities amid concerns of an AI bubble. In such a volatile environment, identifying potentially undervalued stocks becomes crucial for those seeking to capitalize on market inefficiencies and price discrepancies.</p>
<div class="lb-trans"><p>隨着美國市場在科技股承壓和主要指數從歷史高點回落的情況下出現波動，投資者在對人工智能泡沫的擔憂中密切關注機會。在如此動盪的環境中，識別潛在的被低估股票對於那些尋求利用市場低效和價格差異的投資者來説變得至關重要。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In The United States</h3>
<div class="lb-trans"><h3>基於現金流的美國十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Webull (BULL)</td>
<td>$9.16</td>
<td>$17.89</td>
<td>48.8%</td>
</tr>
<tr>
<td>UMB Financial (UMBF)</td>
<td>$118.17</td>
<td>$232.81</td>
<td>49.2%</td>
</tr>
<tr>
<td>Sportradar Group (SRAD)</td>
<td>$23.11</td>
<td>$45.87</td>
<td>49.6%</td>
</tr>
<tr>
<td>Schrödinger (SDGR)</td>
<td>$18.05</td>
<td>$35.42</td>
<td>49%</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.75</td>
<td>$3.43</td>
<td>49%</td>
</tr>
<tr>
<td>Motorcar Parts of America (MPAA)</td>
<td>$13.77</td>
<td>$26.53</td>
<td>48.1%</td>
</tr>
<tr>
<td>Mobileye Global (MBLY)</td>
<td>$11.07</td>
<td>$21.30</td>
<td>48%</td>
</tr>
<tr>
<td>Krystal Biotech (KRYS)</td>
<td>$244.65</td>
<td>$469.32</td>
<td>47.9%</td>
</tr>
<tr>
<td>FirstSun Capital Bancorp (FSUN)</td>
<td>$37.79</td>
<td>$73.32</td>
<td>48.5%</td>
</tr>
<tr>
<td>Columbia Banking System (COLB)</td>
<td>$29.24</td>
<td>$57.69</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>Webull (BULL)</td>
<td>$9.16</td>
<td>$17.89</td>
<td>48.8%</td>
</tr>
<tr>
<td>UMB Financial (UMBF)</td>
<td>$118.17</td>
<td>$232.81</td>
<td>49.2%</td>
</tr>
<tr>
<td>Sportradar Group (SRAD)</td>
<td>$23.11</td>
<td>$45.87</td>
<td>49.6%</td>
</tr>
<tr>
<td>Schrödinger (SDGR)</td>
<td>$18.05</td>
<td>$35.42</td>
<td>49%</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.75</td>
<td>$3.43</td>
<td>49%</td>
</tr>
<tr>
<td>Motorcar Parts of America (MPAA)</td>
<td>$13.77</td>
<td>$26.53</td>
<td>48.1%</td>
</tr>
<tr>
<td>Mobileye Global (MBLY)</td>
<td>$11.07</td>
<td>$21.30</td>
<td>48%</td>
</tr>
<tr>
<td>Krystal Biotech (KRYS)</td>
<td>$244.65</td>
<td>$469.32</td>
<td>47.9%</td>
</tr>
<tr>
<td>FirstSun Capital Bancorp (FSUN)</td>
<td>$37.79</td>
<td>$73.32</td>
<td>48.5%</td>
</tr>
<tr>
<td>Columbia Banking System (COLB)</td>
<td>$29.24</td>
<td>$57.69</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 211 stocks from our Undervalued US Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 211 只被低估美國股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出了一些我們偏好的股票。</p>
</div><h2>Protagonist Therapeutics (PTGX)</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics (PTGX)</h2>
</div><p><strong>Overview:</strong> Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide therapeutics for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases, with a market cap of $5.96 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Protagonist Therapeutics, Inc.是一家生物製藥公司，專注於開發用於血液學和血液疾病以及炎症和免疫調節疾病的肽類治療藥物，市值為 59.6 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its biotechnology segment, specifically focusing on startups, amounting to $209.22 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過其生物技術部門產生收入，特別專注於初創企業，收入達到 2.0922 億美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 18.3%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 18.3%</p>
</div><p>Protagonist Therapeutics is trading at US$95.35, below its estimated fair value of US$116.77, suggesting potential undervaluation based on cash flows. The company forecasts a significant 44% annual earnings growth over the next three years, outpacing the broader market's growth expectations. Despite recent net losses and declining profit margins, Protagonist's promising pipeline includes rusfertide for polycythemia vera, which has received multiple FDA designations and demonstrated positive Phase 3 results.</p>
<div class="lb-trans"><p>Protagonist Therapeutics 的交易價格為 95.35 美元，低於其 116.77 美元的估算公允價值，表明基於現金流的潛在低估。該公司預計未來三年年收益增長將達到 44%，超過更廣泛市場的增長預期。儘管最近出現淨虧損和利潤率下降，Protagonist 的有前景的產品管線包括用於真性紅細胞增多症的 rusfertide，該藥物已獲得多個 FDA 認證並顯示出積極的三期結果。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for Protagonist Therapeutics' business outlook.</li>
<li>Click here to discover the nuances of Protagonist Therapeutics with our detailed financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們最近的增長報告提供了 Protagonist Therapeutics 商業前景的良好預測。</li>
<li>點擊這裏瞭解 Protagonist Therapeutics 的詳細財務健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/dcf?theme=light"/></p>
<p>PTGX Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>PTGX 截至 2025 年 12 月的折現現金流</p>
</div><h2>Atlantic Union Bankshares (AUB)</h2>
<div class="lb-trans"><h2>Atlantic Union Bankshares (AUB)</h2>
</div><p><strong>Overview:</strong> Atlantic Union Bankshares Corporation is a bank holding company for Atlantic Union Bank, offering a range of banking and financial services to consumers and businesses in the United States, with a market cap of approximately $5.22 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Atlantic Union Bankshares Corporation 是一家銀行控股公司，旗下擁有 Atlantic Union Bank，為美國消費者和企業提供一系列銀行和金融服務，市值約為 52.2 億美元。</p>
</div><p><strong>Operations:</strong> Atlantic Union Bankshares generates revenue through its Consumer Banking segment, which accounts for $416.66 million, and its Wholesale Banking segment, contributing $474.99 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> Atlantic Union Bankshares 通過其消費者銀行業務產生收入，收入為 4.1666 億美元，以及其批發銀行業務，貢獻 4.7499 億美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 19.2%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 19.2%</p>
</div><p>Atlantic Union Bankshares, trading at $36.65, is undervalued compared to its fair value estimate of $45.36 based on discounted cash flow analysis. The company anticipates significant earnings growth of 41.5% annually over the next three years, surpassing market expectations. However, recent shareholder dilution and low forecasted return on equity pose challenges. Despite these issues, Atlantic Union's dividend yield remains attractive following a recent increase to 4.5%, supported by strong net interest income growth in recent quarters.</p>
<div class="lb-trans"><p>Atlantic Union Bankshares 的交易價格為 36.65 美元，相較於其基於折現現金流分析的公允價值估算 45.36 美元被低估。該公司預計未來三年年收益增長將達到 41.5%，超過市場預期。然而，最近的股東稀釋和低預期的股本回報率帶來了挑戰。儘管存在這些問題，Atlantic Union 的股息收益率在最近提高至 4.5% 後仍然具有吸引力，得益於最近幾個季度強勁的淨利息收入增長。</p>
</div><ul>
<li>Our expertly prepared growth report on Atlantic Union Bankshares implies its future financial outlook may be stronger than recent results.</li>
<li>Delve into the full analysis health report here for a deeper understanding of Atlantic Union Bankshares.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們精心準備的 Atlantic Union Bankshares 增長報告暗示其未來財務前景可能比最近的結果更強勁。</li>
<li>點擊這裏深入瞭解 Atlantic Union Bankshares 的完整分析健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39dc53db-0edc-4efe-9bce-4b97187c1c94/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/39dc53db-0edc-4efe-9bce-4b97187c1c94/chart/dcf?theme=light"/></p>
<p>AUB Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>AUB 截至 2025 年 12 月的折現現金流</p>
</div><h2>Tapestry (TPR)</h2>
<div class="lb-trans"><h2>Tapestry (TPR)</h2>
</div><p><strong>Overview:</strong> Tapestry, Inc. is a company that offers accessories and lifestyle brand products across North America, Greater China, the rest of Asia, and internationally, with a market cap of approximately $25.21 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Tapestry, Inc.是一家在北美、大中華區、其他亞洲地區及國際市場提供配飾和生活方式品牌產品的公司，市值約為 252.1 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from its segments: Coach at $5.86 billion, Kate Spade at $1.17 billion, and Stuart Weitzman at $176 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入來自其各個業務部門：Coach 為 58.6 億美元，Kate Spade 為 11.7 億美元，Stuart Weitzman 為 1.76 億美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 10.5%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 10.5%</p>
</div><p>Tapestry's recent financial performance highlights its potential as an undervalued stock based on cash flows. The company reported a substantial increase in net income to US$274.8 million for the first quarter, with earnings per share rising significantly from the previous year. Despite high debt levels and insider selling, Tapestry's shares are trading at US$123.21, below the estimated fair value of US$137.73, supported by strong profit growth forecasts of 24.6% annually over the next three years and ongoing share buybacks totaling US$2 billion since November 2024.</p>
<div class="lb-trans"><p>Tapestry 最近的財務表現突顯了其作為基於現金流的被低估股票的潛力。該公司報告第一季度淨收入大幅增加至 2.748 億美元，且每股收益顯著高於去年。儘管債務水平較高和內部人士拋售，Tapestry 的股票交易價格為 123.21 美元，低於估算的公允價值 137.73 美元，得益於未來三年年利潤增長預測為 24.6% 和自 2024 年 11 月以來總計 20 億美元的持續股票回購。</p>
</div><ul>
<li>The growth report we've compiled suggests that Tapestry's future prospects could be on the up.</li>
<li>Click to explore a detailed breakdown of our findings in Tapestry's balance sheet health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們編制的增長報告表明 Tapestry 的未來前景可能向好。</li>
<li>點擊探索我們在 Tapestry 資產負債表健康報告中的詳細發現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4cf6cfa0-4c9d-498d-a423-dd756aaefde7/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/4cf6cfa0-4c9d-498d-a423-dd756aaefde7/chart/dcf?theme=light"/></p>
<p>TPR Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>TPR 截至 2025 年 12 月的折現現金流</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Unlock our comprehensive list of 211 Undervalued US Stocks Based On Cash Flows by clicking here.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏解鎖我們基於現金流的 211 只被低估美國股票的全面列表。</li>
<li>擁有這些企業的股份？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受跨越每個大洲的市場情報免費訪問。</li>
</ul>
</div><h2>Want To Explore Some Alternatives?</h2>
<div class="lb-trans"><h2>想探索一些替代方案嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以應對潛在的市場波動。</li>
<li>通過顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>國防與災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，覆蓋任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

2025 年 12 月可能被低估的三隻股票